Median Effective Dose of Remifentanil for the Prevention of Pain Caused by the Injection of Rocuronium
Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
As a medium-and long-term non-depolarizing muscle relaxant, rocuronium has the advantages of
quick effect, no histamine release and accumulation and no obvious cardiovascular adverse
reactions, so it has been widely used in clinical anesthesia induction. However, when given
intravenously, rocuronium can cause adverse reactions such as injection pain and limb
retraction, which can lead to needle prolapse, extravasation of injection drugs, swelling of
injection site, serious induction delay, and cardiovascular adverse events in severe cases.
Remifentanil is a synthetic opioid drug hydrolyzed by esterase. Compared with other opioid
drugs, remifentanil has the advantages of quick effect, short half-life and short time of
hemodynamic changes, so it is an ideal analgesic in clinical anesthesia. In this study, in
order to provide clinical references, sequential method was used to find the median effective
dose (ED50) by means of pre-intravenous injection of Remifentanil to suppress pain in
rocuronium injection.